ArticleJournal of orthopaedic surgery and research2025
LncRNA MIR22HG promotes fracture healing through down-regulation of miR-10a-5p.
Article in Journal of orthopaedic surgery and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundDelayed fracture healing (DFH) is a common postoperative complication in fractured patients, impairing affects quality of life and increasing financial burden.
objectivesThis study explored the clinical significance of long noncoding RNA (lncRNA) MIR22HG in DFH and its potential mechanisms in promoting fracture healing.
methodsA total of 145 patients with normal healing and 132 patients with DFH were enrolled. Quantitative PCR was used to detect the expression levels of MIR22HG, miR-10a-5p, and osteogenic differentiation-related genes. ROC curves and logistic analysis were performed to evaluate the predictive value of MIR22HG. Using the hFOB 1.19 osteogenic differentiation model, the effects of MIR22HG silencing and co-inhibition of MIR22HG and miR-10a-5p on osteogenic differentiation were explored, and the proliferation and apoptosis were detected via CCK-8 assay and flow cytometry.
resultsSerum MIR22HG were decreased, while miR-10a-5p was elevated in DFH patients. MIR22HG could distinguish DFH patients and predict DFH occurrence. In the hFOB 1.19 osteogenic differentiation model, silencing MIR22HG reduced the expression of osteogenic differentiation markers, inhibited cell proliferation and promoted apoptosis. MIR22HG negatively regulated miR-10a-5p, and miR-10a-5p effectively reversed the inhibitory effect of MIR22HG silencing on hFOB 1.19 cell function.
conclusionMIR22HG promotes fracture healing by sponging miR-10a-5p. Serum MIR22HG is a potential marker for the clinically assisted prediction of DFH occurrence. MIR22HG/miR-10a-5p axis provides a potential molecular target for fracture healing treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.